3.1 C
New York
Friday, December 9, 2022

UK food agency rejects HempToday’s request to document CBD makers

- Advertisement -

The British Food Standards Agency (FSA) rejected a Freedom of Information Request filed by HempToday (HT) regarding companies that currently have products in the agency’s CBD safety review, saying the demand would create too much of a burden for their employees.

HT sought documentation from eight companies whose products reached stage 2 of the FSA system to ensure the safety of new or “new” foods, as well as those of the top 10 companies by the number of orders for products that reached stage one.

Products found in the FSA review, who was troubled From the start, it is assumed that it has fulfilled the initial requirements that allow producers to keep their products in the market pending technical aspects of revision. The rule of thumb requires that these products be on retail shelves before February 12, 2020.

Firms were required to submit receipts, contracts or invoices showing that their products were in circulation prior to the February 2020 closing date, but the Financial Services Authority has no mechanism In place to check those documents. Critics said it was unlikely that both More than 12,000 products that have passed the initial stage of the FSA review meet this requirement.

Sought two batches

HempToday’s request, filed on August 19, 2022 under the UK Freedom of Information Act 2000, is for Certificates of Analysis (COAs), information about the production process and testing methodology, and documentation for products that were on the market prior to February 2020. A history of the companies and the following portfolio numbers, Which were validated in the second phase of the FSA safety review:

  • Pureis: RP07
  • Biological brains: RP11
  • Charlotte’s net: RP230
  • Cannaray & Health in Harmony: RP450
  • Health and Happiness UK Ltd & Bod Healthcare Ltd: RP518
  • 4 MP and CBDex: RP70
  • cbdMD: RP793
  • CBDex: RP85

HT also sought documentation proving market launch dates for the 10 largest portfolios based on the largest number of products approved in the first phase of the FSA review:

  • British Hemp (registered as CBD Health Food Ltd.): RP RP 220, RP 251,
    RP 252, RP 253, RP 254, RP 255, RP 256, RP 325
  • RX Pharmatech Ltd.: RP 427
  • GM Wholesale Limited: RP 438
  • Mile High Labs: RP 349
  • TTS Pharma Ltd: RP 520; RP 521; 639 RP; RP 654; RP 749; RP 771; RP 779; RP
    853; 889 rupees; 890 RP; RP 921; RP 922; RP 981; RP 982
  • PharmaHemp: RP 47; RP 821
  • B3 Labs: RP 106; RP 349
  • Spectrums Europe: RP 46; RP 47; RP 821
  • CBD Hub UK: RP 427
  • Prime CBD: RP 821

the reason of refuse

In response to HT’s request, Hameera Chaudhry-Khan, the agency’s senior freedom of information advisor to the agency’s Knowledge Information Management and Security team, said that keeping track of documents related to when products will start to sell “requires the FSA to search through a large number of files to determine what information the request, the request, [without further clarification,] It would certainly exceed the appropriate cost threshold (£600 / $640) and would therefore be rejected on the basis of excess cost.”

Chaudhry Khan also requested more details regarding the requested information about COAs, processing and testing details.

Succumb to threats

The FSA was inundated with CBD applications earlier this year after stakeholders Question the review process, with some legal action at risk of exclusion. Some of these companies have seen their products rejected while others simply fail to submit applications by the original deadline, March 31, 2021.

Threats and complaints prompted the FSA to reopen the operation after a full year, resulting in a flow of orders that quadrupled the original number of products under review from 3,536 to 12,118. FSA First 2445 . added products, then Double the list again In a later review.

CBD makers in the UK and struggling internationals are clamoring to enter the UK market, which is expected to reach $1 billion over the next few years, amid a massive global meltdown in the sector that includes many of them. on the ropes. Analysts said the UK is now the second largest market for CBD in the world after the US.

Safety Warnings

Meanwhile, the FSA urges caution on the part of the buying public. In a statement earlier this year, the agency suggested “consumers should continue to think carefully before consuming CBD products because we don’t know much about them.” The FSA said women who are pregnant, breastfeeding, or taking medication should not consume CBD products, and urged consumers not to take more than 70mg of CBD per day (about 28 drops of 5% CBD) unless a doctor recommends otherwise.

Reflecting the risk to public safety, the Free Syrian Army also said take note Recent lab reports have shown that some CBD products on the market contain higher levels of THC than are permitted.

HT has asked the Financial Services Authority (FSA) for advice and intends to resubmit a smaller Freedom of Information request.


Are you looking for marijuana growing guides and books about medical cannabis? Then you should not miss our online bookstore with hundreds of books about cannabis, CBD, THC and more!

Grow guide for marijuana beginners.
- Advertisement -THC University

Related Articles


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Stay Connected

- Advertisement -

Latest Articles